×
Choose Speciality

EXPLORE!

LOGIN

Role of GLP-1 RA in T2DM with ASCVD

  2031 Views

Dr Prof PC Manoria, Bhopal    12 January 2022

  • GLP-1 RAs have been established as potent therapeutic drugs for T2DM with multiple pleiotropic effects. They are powered to reduce HbA1c, body weight, with minimal or no hypoglycemia, and also decrease BP.
  • Oral semaglutide is an innovative molecule of this century.
  • Across global PIONEER trials, oral semaglutide has proven its efficacy and achieved HbA1c reduction up to 1.5% and weight reduction up to 5 kg.
  • In patients with baseline HbA1c >9%, oral semaglutide resulted in HbA1c reduction up to 2.6%.
  • Oral semaglutide has proven CV safety in PIONEER-6 with a strong potential for CV death and all-cause death reduction. A larger SOUL trial, to evaluate the long-term CV benefit of oral semaglutide, is ongoing.
  • Efficacy of oral semaglutide was established when given early in therapy, late in therapy and regardless of renal or hepatic impairment.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.